Insys described itself as a pharmaceutical company focused on the research, development, manufacture, and sale of drugs and drug-delivery systems, marketing two products at the time of filing: SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adults, and SYNDROS. The first-day declaration of CEO Andrew G. Long states that approximately 206,741 Subsys prescriptions were dispensed from March 2012 through May 7, 2019.
The debtors tied the filing directly to opioid-related litigation. Long's declaration says Insys and other industry participants had faced an onslaught of opioid litigation beginning in 2017 and that Insys itself was defending approximately 1,000 lawsuits related to the marketing and sale of Subsys. Litigation and settlement costs were consuming large portions of revenue and liquidity, and as of the petition date the debtors reported under $40 million of cash on hand while continuing to lose money. The litigation pressure had also reshaped the company's leadership: Long had become CEO in April 2019 after serving as CFO since August 2017, the general counsel and several functional heads were new since July 2017, and most of the management team and sales force had turned over since 2015.
That overhang was not merely civil. Days before the filing, the founder and four former executives had been convicted of racketeering conspiracy for bribing practitioners to prescribe Subsys, and the company had agreed to a $225 million global resolution of criminal and civil investigations with the Department of Justice. On June 5, 2019, five days before the petition, Insys entered a Corporate Integrity Agreement and Conditional Exclusion Release with HHS-OIG and agreed to stop all marketing and promotion of Subsys upon the earlier of a sale or 90 days after the CIA became effective, a deadline that set the clock for the entire chapter 11 case.
The litigation cost math drove the debtors' first-day strategy. The declaration states that a single government-action trial could exceed $10 million in legal expense, that projected June-to-December 2019 defense spend absent a stay would run $8.5 million to $9.0 million, and that staying the litigation could save roughly $1.0 million to $1.5 million per month. Management framed the case around three goals: sell assets and pursue affirmative causes of action, preserve funds by staying costly litigation, and use bar-date and estimation procedures to shorten the path to a confirmable chapter 11 plan.
Insys entered chapter 11 without funded secured debt and without a debtor-in-possession financing facility. At the first-day hearing, as later quoted in adversary litigation brought by McKesson, counsel characterized the case as unique because it had no secured debt and the debtors held roughly $40 million of cash, which the estates used to fund the cases in lieu of DIP financing or a cash-collateral arrangement.
Because there was no prepetition secured lender, the debtors did not seek DIP financing, a cash-collateral order, or any adequate-protection or carve-out construct of the kind common in secured-debt cases, and counsel confirmed the debtors were not seeking to make payments on prepetition obligations beyond authorized first-day relief. The estates' liquidity instead depended on existing cash plus the proceeds expected from selling the Subsys and Syndros assets.
The value-maximization plan centered on a fast postpetition sale of substantially all assets related to Subsys and the company's other products. In their preliminary-injunction brief, the debtors told the court they did not intend to own or promote Subsys for a prolonged period and would file a global bidding procedures and sale motion to run a flexible and expeditious sale process. The sale timing was governed by the HHS-OIG compliance deadline: the debtors expected that all Subsys sale and marketing activity would necessarily cease by mid-September 2019, and they argued that because the assets were being sold, the government's claims for injunctive relief over marketing practices were effectively, if not literally, moot. The debtors said they were hopeful that the upfront portion of bids received by the end of July 2019 would provide sufficient liquidity to navigate the cases, with an auction anticipated on or about August 5, 2019.
The Subsys assets were ultimately sold to BTcP Pharma as part of the wind-down, and the estate later entered a transition services agreement amendment with Benuvia Therapeutics Inc. as the liquidation proceeded.
By the start of 2020, Insys had wound down operations and was closing its Chandler, Arizona headquarters. The debtors reported the bankruptcy and related corporate actions in securities filings before all equity was cancelled under the confirmed plan.
Rather than litigate its first-day estimation and preliminary-injunction motions to a contested conclusion, the debtors reached an agreed framework with their stakeholders. Under the Agreed Order entered July 2, 2019, the debtors withdrew the estimation motion and held the preliminary-injunction motion in abeyance, with non-stipulated government actions stayed as to the debtors under an agreed Case Protocol; the order expressly disclaimed any admission that those actions were subject to the automatic stay under section 362.
The Case Protocol replaced formal estimation litigation with an information-sharing and mediation process. The Official Committee of Unsecured Creditors would investigate unsecured claims, the debtors would share claims data with the committee, the State Attorneys General group, and the MDL Executive Committee, and the debtors and the committee would co-mediate the allocation of estate value among creditor categories.
The protocol set the following timetable: an anticipated auction around August 5, 2019, a disclosure statement and plan of liquidation by September 2, 2019, a disclosure-statement hearing around October 7, 2019, a confirmation hearing around November 12, 2019, and an effective date around November 22, 2019, all subject to acceleration by agreement. The case ran longer than that template; the confirmation order was entered January 16, 2020, with the effective date on February 18, 2020. The case was also reassigned mid-stream to Judge John T. Dorsey from Judge Kevin Gross.
The confirmed plan is the Second Amended Joint Chapter 11 Plan of Liquidation. When the court approved the plan, it established an opioid recovery trust funded for distribution to creditors, with an initial $160 million targeted to claimants. The plan provided partial repayment to creditors while excluding shareholders entirely, and it included liability releases for non-debtor third parties over opposition from federal regulators. By the time the plan became effective on February 18, 2020, all equity interests were cancelled and the company proceeded with an orderly liquidation.
The non-debtor releases were among the plan's most contested features. Federal regulators objected to extending liability protection to third parties, placing Insys within a broader chapter 11 debate over whether courts may bind non-consenting creditors to releases of claims against non-debtors, a question restructuring commentators had already flagged as unsettled and vulnerable on appeal.
On the effective date, certain assets vested in the Insys Liquidation Trust and William Henrich was appointed trustee. Later trust filings describe a key structural feature: the plan provided for substantive consolidation of the debtors' assets and liabilities for distribution and liquidation purposes. As of the effective date, all assets and liabilities were deemed merged, guarantees were consolidated into single obligations, and any claim against any debtor was treated as one claim against the consolidated debtors.
That substantive-consolidation feature later became a reason the trustee gave for closing the subsidiary cases in 2025, arguing that doing so would not prejudice creditors or interfere with claim reconciliation or distributions because claims against any debtor were already treated as a single consolidated obligation.
The most significant post-confirmation activity has been the trust's recovery litigation. In April 2023, the trust reached a $175 million settlement with former Insys directors to resolve civil claims over oversight failures connected to the company's opioid marketing. The settlement announcement describes an initial $2.35 million payment plus the assignment of insurance claims to the Liquidation Trust to pursue further recovery, structuring much of the value around the directors' insurance coverage rather than personal assets.
Separately, the trust pursued founder John Kapoor for legal fees the company had advanced for his criminal defense. In August 2023, a bankruptcy judge ruled that Kapoor must repay roughly $6 million, holding that his racketeering conviction barred indemnification under Delaware law. That ruling was upheld on appeal in 2024. Kapoor had earlier been sentenced to five and a half years in prison for his role in the bribery scheme, and several other executives were sentenced around the same time.
The trust also generated a body of Delaware preference law. Beginning in early 2021, it filed roughly 53 adversary proceedings to recover allegedly preferential and fraudulent transfers, a campaign that yielded several widely cited rulings. State enforcement continued in parallel, including a $5 million consent judgment between Kapoor and New Jersey in January 2021.
The preference campaign produced rulings that bankruptcy practitioners now cite well beyond this case. In the McKesson litigation, the court held that a prepetition critical vendor order authorizing payments did not, by itself, shield the recipient from later preference liability, a ruling cited for the narrow scope of the critical vendor defense. In a related preference dispute, the court found that the trustee's complaint adequately pled the reasonable due-diligence showing required under section 547(b), and declined to decide whether that showing is an element of the claim or an affirmative defense for the defendant to plead, a question later resolved by a separate Delaware bankruptcy ruling holding it is a claim element.
The estate's insurance litigation proved equally consequential. The court granted summary judgment to XL Specialty, ruling that a sealed, unserved qui tam complaint already constituted a claim against an insured, which triggered a prior-and-pending-litigation exclusion and denied directors-and-officers coverage for the related derivative litigation. Coverage lawyers described the outcome as a nightmare for D&O insureds, since a confidential whistleblower filing the insureds never saw could foreclose coverage for claims asserted years later.
By late 2025, the central live issue was claims reconciliation rather than plan administration. As of the trustee's November 26, 2025 motion to extend the claims-objection deadline, more than 4,000 proofs of claim had been filed, aggregating at least approximately $10.8 billion excluding personal injury claims. The trustee reported having filed 24 omnibus claims objections and having expunged, reclassified, or reduced almost 1,000 claims, and said the trust had reduced asserted administrative and priority claims by more than 95% through settlements and objections. The trust had completely resolved the Class 3 Convenience Class and made distributions to those creditors in August 2023, and had largely resolved Class 4 trade, administrative, and priority claims.
The remaining work ties to both litigation and plan-specific allocation mechanics. The trustee continued to prosecute avoidance actions under sections 547, 548, and 550, and the SMT Allocation Protocol required by the confirmation order had to be developed in a manner substantially consistent with allocation protocols in national opioid litigation or other opioid bankruptcies such as Purdue and Mallinckrodt. The claims-objection deadline, previously extended multiple times, stood at January 30, 2026 before the trustee sought and received an extension through January 29, 2027.
The estate's professional costs are documented in the trust's post-confirmation reporting. The quarter-ending December 31, 2025 report shows cumulative preconfirmation professional-fee and expense payments of $10,199,965, with major line items including FTI Consulting at $3,891,025, Weil Gotshal & Manges as lead counsel at $1,759,519, Lazard Freres at $1,478,864, Richards Layton & Finger at $1,018,507, and Epiq at $1,124,069. Cumulative professional fees and expenses for debtors and committees reached $11,876,616, and cumulative cash disbursements since the effective date totaled $29,618,596, with 100% payment on $705,413 of allowed administrative claims and $165,597 of allowed priority claims.
Distribution activity slowed in early 2026 before resuming. The report for the quarter ending March 31, 2026 showed cumulative disbursements of $29,834,238 with nothing disbursed during that quarter. The most recent report, for the quarter ending June 30, 2026, records $266,667 of cash disbursements during the quarter and cumulative disbursements of $30,100,905 since the effective date, while administrative and priority claims remain paid in full at $705,413 and $165,597 respectively and cumulative debtor-and-committee professional fees stayed unchanged at $11,876,616.
The December 2025 final-decree process simplified the case structure. The trustee asked to close the six subsidiary cases, keep only the lead case open until the trust is fully administered, and route all future pleadings through the lead case, noting that the subsidiary cases were generating $1,500 per quarter in U.S. Trustee fees and that approximately $28,500 in such fees had already been paid. Judge J. Kate Stickles entered the final decree on December 15, 2025, closing the cases for the operating and holding subsidiaries, keeping 19-11292 open as the lead case, and ending post-confirmation reporting and U.S. Trustee fee accrual for the closed subsidiaries while preserving the trustee's ability to keep prosecuting claims, objecting to claims, and making distributions.
| Date | Event |
|---|
| June 5, 2019 | Insys entered the Corporate Integrity Agreement and Conditional Exclusion Release with HHS-OIG |
| June 10, 2019 | Insys and six affiliates filed chapter 11 in Delaware and moved to stay opioid litigation |
| July 2, 2019 | Court entered the Agreed Order staying government actions and approving the Case Protocol |
| January 16, 2020 | Court confirmed the Second Amended Joint Chapter 11 Plan of Liquidation |
| February 18, 2020 | Plan became effective; assets vested in the Insys Liquidation Trust; equity cancelled |
| April 2023 | Trust reached a $175 million settlement with former directors |
| August 2023 | Court ruled Kapoor must repay roughly $6 million in advanced legal fees |
| December 15, 2025 | Court entered the final decree closing the six subsidiary cases |
| July 16, 2026 | Trust filed the quarter-ending June 30, 2026 report, showing $266,667 in disbursements and resumed distribution activity |
| January 29, 2027 | Extended claims-objection deadline |
Who is the liquidating trustee for Insys Therapeutics?
William H. Henrich serves as liquidating trustee of the Insys Liquidation Trust, appointed when the plan became effective on February 18, 2020. The trust holds the estate's assets and prosecutes claims objections, distributions, and recovery litigation in the lead case.
Who is the claims and noticing agent in the Insys case?
Epiq served as the estate's claims and noticing administrator, with cumulative fees of $1,124,069 reflected in the trust's post-confirmation reporting. Future pleadings for the debtors or the trust are filed in lead case 19-11292.
What happened to Insys shareholders in the bankruptcy?
The confirmed liquidation plan cancelled all equity interests and provided no recovery to shareholders. The plan repaid creditors in part through an opioid recovery trust while shutting out equity.
What is the current status of the Insys case?
The six subsidiary cases were closed by final decree on December 15, 2025, leaving only the lead case open. The trust's June 30, 2026 report shows resumed quarterly distributions after a flat first quarter, and the trust continues reconciling more than 4,000 proofs of claim totaling at least $10.8 billion, having filed 24 omnibus objections that reduced asserted administrative and priority claims by more than 95 percent. The claims-objection deadline has been extended to January 29, 2027.
How much has the Insys Liquidation Trust recovered from former insiders?
The trust reached a $175 million settlement with former directors in 2023 and obtained a ruling requiring founder John Kapoor to repay roughly $6 million in advanced legal fees, a decision later upheld on appeal.
Who bought the Subsys assets, and what happened to the company?
The estate sold the Subsys assets to BTcP Pharma as part of the wind-down and later entered a transition services agreement with Benuvia Therapeutics as the liquidation proceeded. Insys ceased operations and closed its Chandler, Arizona headquarters at the start of 2020, and all of its equity was cancelled when the liquidation plan took effect on February 18, 2020.
For related ElevenFlo coverage, see Purdue Pharma's opioid settlement and plan, Acorda Therapeutics' asset sale and liquidating plan, and DirectBuy's liquidation trust and trustee litigation.
